pharmacokinetic interaction between azd3480 and aripiprazole clinical trial intelligence

A Single-Centre, Double-Blind, Randomised, Parallel Group Study of Repeated Oral Doses of AZD3480/Placebo and a Single Dose of Aripiprazole to Evaluate the Pharmacokinetic Interaction Between AZD3480 and Aripiprazole in Healthy Subjects (Phase I)

The study evaluates the pharmacokinetic interaction between AZD3480, an investigational compound by AstraZeneca, and Aripiprazole, an established antipsychotic. Given the increasing focus on drug-drug interactions, particularly in the context of polypharmacy in Alzheimer's disease patients, the findings could inform dosing strategies and safety profiles for concurrent use. The results may enhance AstraZeneca's portfolio in neurodegenerative diseases, potentially positioning AZD3480 as a complementary treatment option alongside existing therapies. Market implications include addressing the unmet need for effective Alzheimer's treatments and navigating competitive landscapes with other neuropharmaceuticals. Diligence considerations should include the safety profile and regulatory pathways for AZD3480, especially in light of its interaction with widely used medications like Aripiprazole.

Matched by target_normalized: Pharmacokinetic interaction between AZD3480 and Aripiprazole